{"entity":{"id":"cgt4859","kind":"drug","name":"CGT4859","aka":[],"tldr":"CGT4859 is an experimental small-molecule drug from Cogent Biosciences in phase 2 trials for biliary tract cancer, aimed at FGFR2.","summary":"CGT4859 is a small-molecule drug developed by Cogent Biosciences. Its target is FGFR2 (the sponsor names FGFR2, FGFR3). The sponsor states: A selective FGFR2/3 inhibitor designed to target tumours with genetic alterations in these fibroblast growth factor receptors. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in biliary tract cancer. The largest, NCT06777316, plans to enrol 110 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of CGT4859","url":"https://clinicaltrials.gov/search?intr=CGT4859"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":["fgfr2"],"drugs":[],"companies":["cogent-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06777316"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"A selective FGFR2/3 inhibitor designed to target tumours with genetic alterations in these fibroblast growth factor receptors.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cgt4859/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"company":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/"}],"trial":[{"id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","route":"/trials/nct06777316/"}]}}